Loading...

Protagonist Therapeutics

BST:PGF
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PGF
BST
$244M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The last earnings update was 40 days ago. More info.


Add to Portfolio Compare Print
  • Protagonist Therapeutics has significant price volatility in the past 3 months.
PGF Share Price and Events
7 Day Returns
-7.3%
BST:PGF
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
27.4%
BST:PGF
-10.2%
DE Biotechs
-6%
DE Market
PGF Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Protagonist Therapeutics (PGF) -7.3% -23.4% 32.8% 27.4% - -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • PGF outperformed the Biotechs industry which returned -10.2% over the past year.
  • PGF outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
PGF
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Protagonist Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Protagonist Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €9.095.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Protagonist Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Protagonist Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:PGF PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.74
NasdaqGM:PTGX Share Price ** NasdaqGM (2019-04-18) in USD $10.47
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Protagonist Therapeutics.

BST:PGF PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:PTGX Share Price ÷ EPS (both in USD)

= 10.47 ÷ -1.74

-6.02x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Protagonist Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Protagonist Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Protagonist Therapeutics's expected growth come at a high price?
Raw Data
BST:PGF PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.02x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
1.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Protagonist Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Protagonist Therapeutics's assets?
Raw Data
BST:PGF PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $4.85
NasdaqGM:PTGX Share Price * NasdaqGM (2019-04-18) in USD $10.47
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
BST:PGF PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:PTGX Share Price ÷ Book Value per Share (both in USD)

= 10.47 ÷ 4.85

2.16x

* Primary Listing of Protagonist Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Protagonist Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Protagonist Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Protagonist Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Protagonist Therapeutics expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
1.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Protagonist Therapeutics expected to grow at an attractive rate?
  • Unable to compare Protagonist Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Protagonist Therapeutics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Protagonist Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
BST:PGF Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:PGF Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 1.4%
BST:PGF Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 30.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:PGF Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:PGF Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 128 -52 -27 2
2022-12-31 75 -69 -75 2
2021-12-31 113 -76 -7 2
2020-12-31 13 -90 -98 3
2019-12-31 21 -50 -65 5
BST:PGF Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 31 -50 -39
2018-09-30 40 -54 -28
2018-06-30 43 -4 -24
2018-03-31 31 -1 -31
2017-12-31 20 4 -37
2017-09-30 9 8 -45
2017-06-30 -39 -48
2017-03-31 -35 -40
2016-12-31 -30 -38
2016-09-30 -25 -32
2016-06-30 -22 -28
2016-03-31 -17 -24

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Protagonist Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Protagonist Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:PGF Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Protagonist Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:PGF Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.94 -0.94 -0.94 1.00
2022-12-31 -2.71 -2.71 -2.71 1.00
2021-12-31 -0.69 1.50 -2.87 2.00
2020-12-31 -3.01 -2.86 -3.21 3.00
2019-12-31 -2.54 -2.23 -3.06 4.00
BST:PGF Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.74
2018-09-30 -1.32
2018-06-30 -1.22
2018-03-31 -1.62
2017-12-31 -2.09
2017-09-30 -2.68
2017-06-30 -3.24
2017-03-31 -3.77
2016-12-31 -5.80
2016-09-30 -13.50
2016-06-30 -92.56
2016-03-31 -90.21

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Protagonist Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Protagonist Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Protagonist Therapeutics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Protagonist Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Protagonist Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Protagonist Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Protagonist Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Protagonist Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Protagonist Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Protagonist Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:PGF Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 30.93 -38.92 13.70 59.50
2018-09-30 39.85 -28.11 13.25 56.97
2018-06-30 42.52 -24.20 12.48 56.00
2018-03-31 30.84 -30.52 12.43 50.27
2017-12-31 20.06 -36.96 11.78 46.18
2017-09-30 8.78 -45.15 11.28 43.28
2017-06-30 -47.71 10.27 37.67
2017-03-31 -40.05 8.54 31.36
2016-12-31 -37.74 6.96 25.71
2016-09-30 -32.02 5.20 21.08
2016-06-30 -28.13 4.48 18.67
2016-03-31 -24.02 3.87 15.27
2015-12-31 -14.93 2.96 11.83
2014-12-31 -11.22 1.86 7.46

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Protagonist Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Protagonist Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Protagonist Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Protagonist Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Protagonist Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Protagonist Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Protagonist Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Protagonist Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Protagonist Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Protagonist Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Protagonist Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Protagonist Therapeutics Company Filings, last reported 3 months ago.

BST:PGF Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 112.52 0.00 128.85
2018-09-30 123.96 0.00 138.52
2018-06-30 107.66 0.00 125.17
2018-03-31 114.62 0.00 134.96
2017-12-31 120.63 0.00 144.00
2017-09-30 57.84 0.00 93.59
2017-06-30 61.03 0.00 64.49
2017-03-31 74.89 0.00 63.25
2016-12-31 87.56 0.00 77.60
2016-09-30 97.49 0.00 98.52
2016-06-30 20.41 0.00 20.18
2016-03-31 27.39 0.00 29.02
2015-12-31 11.72 0.00 11.92
2014-12-31 8.98 0.00 9.32
  • Protagonist Therapeutics has no debt.
  • Protagonist Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Protagonist Therapeutics has sufficient cash runway for 2.6 years based on current free cash flow.
  • Protagonist Therapeutics has sufficient cash runway for 2.3 years if free cash flow continues to grow at historical rates of 13.4% each year.
X
Financial health checks
We assess Protagonist Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Protagonist Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Protagonist Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Protagonist Therapeutics dividends.
If you bought €2,000 of Protagonist Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Protagonist Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Protagonist Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:PGF Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:PGF Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Protagonist Therapeutics has not reported any payouts.
  • Unable to verify if Protagonist Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Protagonist Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Protagonist Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Protagonist Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Protagonist Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Protagonist Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Protagonist Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Dinesh Patel
COMPENSATION $790,088
AGE 61
TENURE AS CEO 10.3 years
CEO Bio

Dr. Dinesh V. Patel, Ph.D., has been the Chief Executive Officer and President at Protagonist Therapeutics, Inc. since December 2008 and its Interim Chief Financial Officer since January 11, 2019. Dr. Patel serves as secretary of Protagonist Therapeutics, Inc. Dr. Patel served as Consultant of Arête Therapeutics, Inc. since July 2008. He served as Chief Executive of Arête Therapeutics Inc., from February 2006 to July 2008 and also served as its President since 2006 until July 2008. Dr. Patel Co-founded Miikana Therapeutics Inc., in 2002 and served as its President from 2003 to 2005 and served as its Chief Operating Officer. He served as Senior Vice President of drug discovery and licensing of Vicuron Pharmaceuticals Inc., (formerly, Versicor) since 1996 until July 2003. Dr. Patel has over 18 years of experience in the pharmaceutical, biotech and biopharmaceutical industry. Prior to Miikana, Dr. Patel held positions of increasing responsibility at Versicor (later renamed Vicuron and which was acquired by Pfizer in 2015), from 1996 to 2003. At Versicor, he led their internal and collaborative research programs (Pharmacia, Novartis) and actively participated in various financing activities. Dr. Patel served as Director of Drug Discovery of Affymax and led the combinatorial chemistry application efforts aimed at changing the drug discovery paradigm. Dr. Patel was a medicinal chemist at BristolMyers Squibb from 1985 to 1193 and served in various positions including group leader. Dr. Patel has a proven track record of incubating and leading projects from ‘Targets to INDs’. He serves as a Director of Protagonist Therapeutics, Inc. since December 2008. He served as Director of Arête Therapeutics, Inc. until July 2008. He has more than 100 patents and publications to his credit. Dr. Patel was a director of chemistry at the combinatorial chemistry company Affymax, from 1993 to 1996. Prior to that, he was the Chief Executive Officer of Miikana Therapeutics, an oncology-based company, from 2003 until it was acquired by Entremed (later renamed CASI Pharmaceuticals) in 2005. Dr. Patel has more than 30 years of executive, entrepreneurial and scientific experience spanning the pharmaceutical, biotechnology and biopharmaceutical industries. Dr. Patel received his Ph.D. in Organic Chemistry from Rutgers, The State University of New Jersey and conducted Post-Doctoral research at the University of Wisconsin, Madison. He holds B.S. in Industrial Chemistry from S. P. University, Vallabh Vidyanagar, India.

CEO Compensation
  • Dinesh's compensation has been consistent with company performance over the past year.
  • Dinesh's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Protagonist Therapeutics management team in years:

4.8
Average Tenure
61
Average Age
  • The tenure for the Protagonist Therapeutics management team is about average.
Management Team

Dinesh Patel

TITLE
CEO, President
COMPENSATION
$790K
AGE
61
TENURE
10.3 yrs

Richard Shames

TITLE
Chief Medical Officer
COMPENSATION
$539K
AGE
58
TENURE
3.7 yrs

David Liu

TITLE
Chief Scientific Officer and Head of Research & Development
COMPENSATION
$552K
AGE
68
TENURE
5.9 yrs

Mark Smythe

TITLE
Vice President of Technology
AGE
53
TENURE
6.3 yrs

Sam Saks

TITLE
Chief Development Officer
AGE
63
TENURE
0.9 yrs

Suneel Gupta

TITLE
Executive Vice President of Clinical Operations & Clinical Pharmacology
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Protagonist Therapeutics board of directors in years:

9.3
Average Tenure
60
Average Age
  • The tenure for the Protagonist Therapeutics board of directors is about average.
Board of Directors

Barry Selick

TITLE
Chairman
COMPENSATION
$143K
AGE
64

Dinesh Patel

TITLE
CEO, President
COMPENSATION
$790K
AGE
61
TENURE
10.3 yrs

Armen Shanafelt

TITLE
Director
COMPENSATION
$114K
AGE
59
TENURE
9.3 yrs

Chaitan Khosla

TITLE
Director & Chairman of Scientific Advisory Board
COMPENSATION
$113K
AGE
53

Will Waddill

TITLE
Director
COMPENSATION
$119K
AGE
61
TENURE
2.8 yrs

Charles Craik

TITLE
Scientific Advisor

Mark Gallop

TITLE
Scientific Advisor
AGE
55

Aida Habtezion

TITLE
Clinical Advisor

Wayne Lencer

TITLE
Clinical Advisor

Ellen Scherl

TITLE
Clinical Advisor
Who owns this company?
Recent Insider Trading
  • Protagonist Therapeutics insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
04. Mar 19 Sell David Liu Individual 01. Mar 19 01. Mar 19 -810 €7.06 €-5,717
04. Mar 19 Sell Dinesh Patel Individual 01. Mar 19 01. Mar 19 -2,183 €7.06 €-15,407
04. Mar 19 Sell Richard Shames Individual 01. Mar 19 01. Mar 19 -657 €7.06 €-4,637
08. Feb 19 Sell Dinesh Patel Individual 06. Feb 19 06. Feb 19 -10,909 €7.12 €-74,188
08. Feb 19 Sell Richard Shames Individual 06. Feb 19 06. Feb 19 -2,778 €7.16 €-18,901
08. Feb 19 Sell David Liu Individual 06. Feb 19 06. Feb 19 -3,821 €6.80 €-25,982
21. May 18 Sell Canaan Partners Company 17. May 18 17. May 18 -38,968 €5.16 €-201,208
16. May 18 Sell Canaan Partners Company 14. May 18 16. May 18 -164,747 €5.50 €-898,031
X
Management checks
We assess Protagonist Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Protagonist Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD. It is also involved in researching oral and injectable peptide-based product candidates for a range of conditions, including gastrointestinal diseases. The company was founded in 2006 and is headquartered in Newark, California.

Details
Name: Protagonist Therapeutics, Inc.
PGF
Exchange: BST
Founded: 2006
$217,359,410
23,347,066
Website: http://www.protagonist-inc.com
Address: Protagonist Therapeutics, Inc.
7707 Gateway Boulevard,
Suite 140,
Newark,
California, 94560,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM PTGX Common Stock Nasdaq Global Market US USD 11. Aug 2016
BST PGF Common Stock Boerse-Stuttgart DE EUR 11. Aug 2016
Number of employees
Current staff
Staff numbers
64
Protagonist Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:58
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/14
Last earnings filing: 2019/03/12
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.